Advertisement
UK markets closed

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     

  • AIM

    794.02
    +1.52 (+0.19%)
     

  • GBP/EUR

    1.1680
    +0.0026 (+0.22%)
     

  • GBP/USD

    1.2701
    +0.0030 (+0.24%)
     

  • Bitcoin GBP

    52,675.40
    +1,311.85 (+2.55%)
     

  • CMC Crypto 200

    1,365.56
    -8.29 (-0.60%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • DOW

    40,003.59
    +134.21 (+0.34%)
     

  • CRUDE OIL

    79.96
    +0.73 (+0.92%)
     

  • GOLD FUTURES

    2,421.90
    +36.40 (+1.53%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     
Property:

9 houses with great-looking gardens

Check out these homes if inspiring outside space tops your property wish list

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

PR Newswire
·2-min read

SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

(PRNewsfoto/Nektar Therapeutics)
(PRNewsfoto/Nektar Therapeutics)

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 9, 2024.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

ADVERTISEMENT

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:                                                                                             

Vivian Wu of Nektar Therapeutics

(628) 895-0661

For Media:

David Rosen of Argot Partners

(212) 600-1902

david.rosen@argotpartners.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-2024-on-thursday-may-9-2024-after-close-of-us-based-financial-markets-302135009.html

SOURCE Nektar Therapeutics